DMU2105 is a potent and selective inhibitor of cytochrome P450 1B1 (CYP1B1), exhibiting 74- and 120-fold selectivity for CYP1B1 over CYP1A1 and CYP1A2, respectively; it may enhance cellular toxicity mediated by CYP1B1 inhibition, as evidenced by a reduced EC50 of cisplatin in CYP1B1-expressing cells.